Abraham Ceesay, Rapport Therapeutics CEO
Rapport, a clinical-stage neuroscience biotech, files for IPO
Rapport Therapeutics, which emerged out of Johnson & Johnson’s neuroscience unit last year, has submitted its pitch for a Nasdaq listing.
The Boston-based startup plans …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.